Therefore, the data strongly suggest the potential therapeutic value of LNX1, at least in tumors retaining functional p53, based on which LNX1-targetable drugs could be developed for treating patients with cancer retaining wild-type p53. The gene discussed is LNX1; the disease is cancer.